Skip to main content

Month: March 2023

Automotive Finco Corp. Announces Semi-annual Cash Dividends

Not for distribution to United States newswire services or for dissemination in the United States. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. TORONTO, March 03, 2023 (GLOBE NEWSWIRE) — Automotive Finco Corp. (NEX: AFCC-H) (the “Company”) announces a change to the frequency of its dividend distributions from monthly to semi-annually to align with expected cash flow from its current loan investment of $21 mm, announced on November 18, 2022. Accordingly the monthly cash dividend of $0.0171 / common share has been suspended effective March 1, 2023. The Company intends to pay semi-annual dividends to be paid at the end of June and December at the same effective rate of $0.205 / common share per annum for the near term. The declaration, amount...

Continue reading

Stereotaxis Reports 2022 Full Year Financial Results

ST. LOUIS, March 03, 2023 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2022. “This year is poised to be an important and exciting year for Stereotaxis, as we bring multiple strategic innovations to key regulatory and commercial milestones,” said David Fischel, Chairman and CEO. “This transition to a new product ecosystem is strategically transformational as it addresses structural inefficiencies, dependencies and limitations while setting us up for significant growth.” “Technology developments continue to advance well, and we expect regulatory approvals and commercial launches this year for our proprietary robotically-navigated ablation catheter,...

Continue reading

Cloud Analytics Market is Projected to Surpass USD 71.89 Billion by 2028 with a CAGR of 20.9% from 2022 to 2028; Increasing Reliance on Cloud-Based Data Solutions to Manage and Analyze Critical Data Emerges as the Key Market Driver

SkyQuest has produced a comprehensive report on the cloud analytics market, utilizing a robust methodology to provide an in-depth industry analysis. The report encompasses a SWOT analysis, technology assessment, economic evaluation, product benchmarking, recent developments, and accurate forecasting to offer reliable and precise insights into the market. This report is beneficial in comprehending the present market situation, identifying key players operating in the market, and analyzing their market share, strategies, and key developments. Westford, USA,, March 03, 2023 (GLOBE NEWSWIRE) — The cloud analytics market is witnessing significant dominance by North America, followed by Europe, due to businesses’ growing adoption of digital platforms and the rising demand for data connectivity through cloud environments. With the...

Continue reading

Maris-Tech Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

REHOVOT, Israel, March 03, 2023 (GLOBE NEWSWIRE) — Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a B2B provider of intelligent video transmission technology with AI acceleration for edge platforms, reported the receipt of a formal notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Listing Rule 5550(a)(2), which requires the Company’s ordinary shares to maintain a minimum bid price of $1.00 per share. The Nasdaq staff made this determination of compliance after the closing bid price of the Company’s ordinary shares was at $1.00 per share or greater for the prior 20 consecutive business days. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers the prior bid price deficiency...

Continue reading

Correction: Zealand Pharma convenes its Annual General Meeting 2023

Correction: Company Announcement – No. 2 / 2023Zealand convenes its Annual General Meeting 2023   Notice to convene the Annual General Meeting of Zealand Pharma A/S (CVR no. 20 04 50 78) (the “Company”). The Board of Directors of the Company hereby convenes the Annual General Meeting of the Company to be held on: Wednesday, March 29 2023 at 3:00 pm (CEST)  The Annual General Meeting will be held as a partly electronic general meeting with the possibility of attending electronically or in person (hybrid meeting). The Annual General Meeting will be held electronically via the virtual portal hosted by Computershare A/S, and physically at the Company’s registered address Sydmarken 11, DK-2860 Søborg.  Please find further information in the updated accompanying attachment [item 3, page 2 corrected...

Continue reading

EzFill Adds 10 Fleet Accounts in February

New Fleet Accounts in First Two Months of New Year Reach 19 MIAMI, FL, March 03, 2023 (GLOBE NEWSWIRE) — EzFill Holdings, Inc. (“EzFill” or the “Company”) (NASDAQ: EZFL), a pioneer and emerging leader in the mobile fuel industry, announced that it added 10 new fleet accounts during the month of February, bringing the year-to-date new fleet account number to 19. The new fleet accounts include companies in the following industries: home improvement, auto rental, pet grooming, care providers, food service and distribution, pool supplies and moving and storage. EzFill will provide regularly scheduled fuel deliveries for an aggregate of approximately 140 vehicles that are expected to add up to approximately 233,000 additional gallons of fuel delivered annually. Mike McConnell, EzFill Chief Executive Officer, commented, “We had another...

Continue reading

Cidara Therapeutics Announces Pricing of Public Offerings of Common Stock and Preferred Stock

SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced the pricing of concurrent but separate underwritten public offerings of 9,640,000 shares of its common stock and 286,000 shares of its Series X Convertible Preferred Stock (each share of which is initially convertible into 10 shares of common stock), for aggregate expected gross proceeds of approximately $17.5 million, before deducting underwriting discounts and commissions and estimated offering expenses. The offerings are expected to close on or about March 7, 2023, subject to satisfaction of customary closing conditions. The closing of each offering is not contingent upon the closing...

Continue reading

Morphic to Present at TD Cowen 43rd Annual Health Care Conference

WALTHAM, Mass., March 03, 2023 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate a panel discussion focused on new approached to treat gastroenterological diseases and a corporate fireside chat at the TD Cowen 43rd Annual Health Care Conference. Presentation Information GI/Microbiome Panel Discussion9:10 AM ET, Monday March 6, 2023 Fireside Chat11:10 AM ET, Monday, March 6, 2023 A live webcast of the presentations will be available on the Investor section of Morphic’s website at www.morphictx.com. An archived replay will be available on the company’s website following the conference. About Morphic TherapeuticMorphic Therapeutic is a biopharmaceutical...

Continue reading

Treace Medical Announces Settlement of Lawsuit Again Fusion Orthopedics

PONTE VEDRA, Fla., March 03, 2023 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) jointly announces with Fusion Orthopedics, LLC (“Fusion Orthopedics”) that they have reached an amicable resolution of the litigation between the parties. Treace Medical filed the lawsuit on March 29, 2022 against Fusion Orthopedics in the United States District Court for the District of Arizona, alleging patent, trademark, and copyright infringement, as well as various unfair trade practices based on Fusion Orthopedics’ use, sale, and promotion of the Lapilock 4D Advanced Bunion Surgery, including false advertising and unfair competition. Fusion Orthopedics subsequently...

Continue reading

CareCloud Declares Dividends on Non-Convertible Series A and Series B Cumulative Redeemable Perpetual Preferred Stock

SOMERSET, N.J., March 03, 2023 (GLOBE NEWSWIRE) — CareCloud, Inc. (the “Company”) (Nasdaq: CCLD, CCLDP, CCLDO), a leader in healthcare technology solutions for medical practices and health systems nationwide, today announced that its Board of Directors has declared monthly cash dividends for its 11% Series A Cumulative Redeemable Perpetual Preferred Stock (“Series A Preferred Stock”) and its 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock (“Series B Preferred Stock”) for March, April and May 2023. This represents 91 consecutive months of dividends declared since the Series A Preferred Stock was initially sold in November 2015. The following table shows the monthly dividends and associated record and payment dates:    March 2023     April 2023     May 2023  Series A dividend per share   $ 0.22917     $ 0.22917     $ 0.22917  Series...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.